Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial (P10-15.009)

Key Points

• To evaluate the tolerability, safety, and efficacy of atogepant compared to topiramate in migraine prevention.
• Participants received either atogepant or topiramate for migraine prevention.
• Study assessed tolerability and safety outcomes alongside efficacy measures.
• Atogepant demonstrated superior tolerability compared to topiramate.
• Efficacy outcomes favored atogepant in reducing migraine frequency.
• Safety profiles were analyzed, indicating fewer adverse effects with atogepant.